Objectives: EUCAST developed an antibiotic susceptibility testing method for Haemophilus influenzae. We assessed the EUCAST testing method and EUCAST clinical breakpoints and newly proposed epidemiological cut-off values against H. influenzae clinical isolates with known molecular mechanisms of resistance to b-lactam antibiotics.
Introduction
Haemophilus influenzae is a human pathogen that causes invasive and respiratory infections in children and adults. Resistance or decreased susceptibility to b-lactam antibiotics in this pathogen is mostly due to b-lactamase production and decreased PBP3 affinity (BLNAR phenotype); both mechanisms can be found in the same isolate. 1 In vitro detection of aminopenicillin resistance due to the BLNAR phenotype may be challenging because strains with altered PBP3 exhibit a range of ampicillin MICs that cluster around the resistance breakpoint. 2, 3 Different growth media have been developed for susceptibility testing of H. influenzae, with Haemophilus Test Medium (HTM), which was adopted by the CLSI, 4, 5 being the reference culture method. EUCAST has proposed a disc diffusion testing method for H. influenzae. 6 The aim of this study was to evaluate the H. influenzae EUCAST disc susceptibility testing method for b-lactam antibiotics by challenging it with a well-characterized collection of clinical isolates with known mechanisms of resistance. 2 We studied whether the EUCAST method could separate H. influenzae resistance classes using either EUCAST clinical breakpoints or newly proposed epidemiological cut-off values.
Materials and methods

Test isolates
We used a study collection of 89 H. influenzae clinical isolates for which the resistance mechanisms to b-lactam antibiotics have been determined previously by our group. 2 In the collection, four genotypes of ampicillin susceptibility were represented: 30 isolates were b-lactamase negative, but had mutations in their ftsI gene causing reduced susceptibility to ampicillin (genotype gBLNAR); 20 isolates were b-lactamase positive and ampicillin resistant, but had no ftsI mutation (genotype gBLPAR); 15 isolates were b-lactamase positive and had mutations in the ftsI gene (genotype gBLPACR); and 24 isolates were b-lactamase negative and ampicillin susceptible without resistance mechanism (genotype gBLNAS). All b-lactamase-positive isolates were TEM-1.
Isolates belonging to gBLNAR and gBLPACR genotypes were selected according to their PBP3 amino acid substitutions in such a way that the most common mutation patterns described in European gBLNAR isolates were represented. 2 Four isolates belonged to group IIa, 12 to group IIb (7 gBLNAR and 5 gBLPACR), 22 to group IIc (12 gBLNAR and 10 gBLPACR) and 7 to group III-like.
2,7
Susceptibility testing
Disc diffusion
Antibiotic susceptibility testing was performed by the disc diffusion method following the EUCAST guidelines; 6 Mueller -Hinton agar was supplemented with 5% horse blood and 20 mg/L b-NAD (Sigma-Aldrich). Plates were inoculated with samples of each strain and adjusted to a turbidity of 0.5 McFarland with a photometric device (spectrophotometer SmartSpec Plus, Bio-Rad). Antibiotic discs were applied to the dried surface of the inoculated agar and further incubated at 378C for 18+2 h in a 5% CO 2 atmosphere.
Antibiotic discs tested and charges were penicillin (10 U), ampicillin (2 and 10 mg), amoxicillin (2 and 10 mg), amoxicillin/clavulanic acid (2/1 and 20/10 mg), cefaclor (30 mg), cefuroxime (30 mg), cefotaxime (30 mg), cefixime (5 mg) and cefoxitin (30 mg).
H. influenzae NCTC 8468 was used as a susceptibility quality control strain, as recommended by EUCAST. 6 The sizes of inhibition zone diameters were independently read by at least two of the authors. Final inhibition zone diameters (in millimetres) were the averages of the independent readings.
Definitions
In this study the terms clinical breakpoint and epidemiological cut-off value were used according to EUCAST definitions and guidelines. 8, 9 MIC determination by Etest
The MICs of ampicillin and amoxicillin/clavulanic acid were determined by Etest (AB-Biodisk, Solna, Sweden) using the EUCAST testing method as described previously. 2 
Analysis of results
Genotype determination as determined by PCR amplification and DNA sequencing of ftsI and bla TEM genes was considered the gold standard method against which the EUCAST disc diffusion method was tested.
Very major errors were defined as results that indicated a lack of modifications in PBP3 (gBLNAS or gBLPAR) by disc diffusion when they were gBLNAR or gBLPACR by the gold standard method. Major errors were classified as results that indicated the presence of mutations in the ftsI gene (gBLNAR or gBLPACR) by disc diffusion when they had no mutations in PBP3 (gBLNAS or gBLPAR) by the gold standard method.
Results and discussion
Population distribution of inhibition zone diameters by resistance mechanisms
In general, none of the 12 discs tested fully separated between the gBLNAS and gBLNAR populations ( Figure S1 , available as Supplementary data at JAC Online); due to the high degree of overlap, the following discs were found to be of little use for this purpose: ampicillin 10 mg, amoxicillin 10 mg, amoxicillin/clavulanic acid 20/10 mg, cefaclor 30 mg, cefotaxime 30 mg, and cefixime 5 mg. Usually low-charge discs offered better separation between these two populations, but none of them was perfect; the following discs had fewer overlapping zones: penicillin 10 U, ampicillin 2 mg, amoxicillin 2 mg, amoxicillin/clavulanic acid 2/1 mg, and cefuroxime 30 mg, and they were considered for further analysis.
Separation between fully susceptible (gBLNAS) and b-lactamase-producing (gBLPAR and gBLPACR) isolates can be easily accomplished by performing a simple b-lactamase test; however, further separation between the gBLPAR and gBLPACR populations can be challenging, although they could be tentatively distinguished by the amoxicillin/clavulanic acid 2/1 and 20/10 mg, cefuroxime 30 mg, and cefoxitin 30 mg discs ( Figure S1 , available as Supplementary data at JAC Online).
Clinical breakpoints and resistance mechanisms gBLNAR detection by the disc method
The following discs had better balanced values for the gBLNAR identification: ampicillin 2 mg, amoxicillin/clavulanic acid 2/1 mg disc, and cefuroxime 30 mg ( Table 1 ). The clinical ampicillin 2 mg disc breakpoint, currently proposed by EUCAST (R ,16 mm), had a sensitivity of 73.3% and a specificity of 79.2% (Table 1) .
gBLPACR detection by the disc method
The EUCAST clinical zone diameter breakpoint recommended with the cefuroxime 30 mg disc showed very high values of sensitivity, specificity and positive predictive value (PPV) for the detection of gBLPACR isolates (Table 1) .
gBLNAR and gBLPACR detection by Etest
All the proposed EUCAST clinical MICs breakpoints have excellent specificity and PPV, but very low sensitivity, and then high very major errors because many gBLNAR isolates had MICs of 1 mg/L for ampicillin or 2 mg/L for amoxicillin by Etest (Table 1) and also by microdilution, as previously published. 2 
Newly suggested epidemiological cut-offs gBLNAR epidemiological cut-offs
By decreasing the zone diameter breakpoint for amoxicillin 2 mg to 14 mm, specificity improved to 83.3% (Table 1) . Søndergaard et al. 10 suggested an epidemiological cut-off value of 19/20 mm García-Cobos et al.
with ampicillin 2 mg disc for the detection of isolates with the N526-K mutation in ftsI with a specificity of 99%. A penicillin 10 U (currently not recommended by EUCAST) breakpoint ,24 mm had sensitivity, specificity and PPVs .85% (Table 1) . A benzylpenicillin disc of 1 U, not tested in this study, is now being proposed by EUCAST. 8 Detection of gBLNAR for epidemiological purposes can also be improved by using an MIC cut-off value (as determined by Etest) of R ≥1 mg/L for ampicillin (Table 1) .
gBLPACR epidemiological cut-offs
Our tentatively proposed epidemiological cut-off values for amoxicillin/clavulanic acid 2/1 mg (R,16 mm) and 20/10 mg (R ,25 mm) discs had good sensitivity and specificity values (Table 1) . Also, the cefotaxime and cefoxitin discs may have some interest according to our results (Table 1) .
By Etest, the gBLPACR detection sensitivity percentage may be markedly improved by using an MIC breakpoint of R .1 mg/L as the epidemiological cut-off for amoxicillin/clavulanic acid (Table 1) . Some cephalosporin discs, such as cefaclor, cefoxitin and cefuroxime (30 mg each), had been proposed for the detection of the ftsI mutation N526-K. 10 In the present study, the cefoxitin 30 mg disc (and a zone diameter breakpoint of 22 mm) was found to be useful for the detection of gBLPACR isolates (Table 1) .
Considering the above data, Figure 1 shows a suggested easy-to-use algorithm for screening of gBLNAS, gBLNAR, gBLPAR and gBLPACR populations of H. influenzae using the EUCAST test method. The algorithm utilizes a b-lactamase test and a cefuroxime 30 mg disc; other antibiotic discs could also be used according to data depicted in Table 1 . It should be emphasized that the final detection of resistance genotypes, such as gBLNAR, requires PCR amplification and DNA sequencing of the ftsI gene.
Conclusions
In this study, we provide several findings of microbiological and epidemiological interest: (i) the EUCAST proposed susceptibility testing method for H. influenzae may separate the three most The amoxicillin 2 mg and penicillin 10 U discs are currently not recommended by EUCAST. 
